Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3,215

Beguš is a linguist at the University of California, Berkeley. He got the chance, last summer, to observe sperm whales in their wild Caribbean habitat off the coast of the island nation of Dominica. With him were marine biologists and roboticists. There were also cryptographers and experts in other fields. All have been working together to listen to sperm whales and figure out what they might be saying.

They call this Project CETI. That’s short for Cetacean Translation Initiative (because sperm whales are a type of cetacean).

AI translates human languages with ease. Researchers are now using this tech to analyze the sounds of whales, rodents and many other animals.

Read more | >

Here is another story from web bike world: “Is water the future of motorbikes”

https://www.webbikeworld.com/water-power-future-motorbikes/

Circa: 2016.

With all this attention to electric, people are making the same mistake as putting all attention to petrol (fossil fuels). Since 2016 Sao Paulo inventor Ricardo Azevedo has said his T Power H20 bike can even run on polluted water.

A motorcycle that runs on water! It will go about 300 miles on just one liter of water. A Brazilian man has modified a small motorcycle to run on hydrogen. We all know that an ICE (internal combustion engine) will run on hydrogen, so there’s nothing new there.

Continue reading “Motorcycle Goes 300 Miles on 1 Liter of Water” | >

Wildfires fueled by climate change have ravaged communities from Maui to the Mediterranean this summer, killing many people, exhausting firefighters and fueling demand for new solutions. Enter artificial intelligence.

Firefighters and startups are using AI-enabled cameras to scan the horizon for signs of smoke. A German company is building a constellation of satellites to detect fires from space. And Microsoft is using AI models to predict where the next blaze could be sparked.

With wildfires becoming larger and more intense as the world warms, firefighters, utilities and governments are scrambling to get ahead of the flames by tapping into the latest AI technology—which has stirred both fear and excitement for its potential to transform life. While increasingly stretched first responders hope AI offers them a leg up, humans are still needed to check that the tech is accurate.

Read more | >

“That’s what makes this research unique from a scientific standpoint. The study participant can walk over to the lab, have the blood drawn and within hours their specimen can be transferred to the on-site facility where the process of biomanufacturing the vaccine begins,” says Dr. Block. “That would not be possible with an outside manufacturer.”

A deadly form of reproductive system cancer

Ovarian cancer is the deadliest form of gynecologic cancer. It often is not diagnosed until advanced stages, when it is less treatable. Even with standard surgery and chemotherapy, tumors return in up to 70% of women. The outcome is often poor. 19,000 women in the U.S. are diagnosed with ovarian cancer every year and more than 13,000 die from it, according to the American Cancer Society.

Read more | >

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.
Enter Code: ConquerAging.

Epigenetic Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

At-Home Blood Testing (SiPhox Health): https://getquantify.io/mlustgarten.

Continue reading “Albumin, CRP, and Creatinine: Better Markers Of Longevity Than Lipoproteins And Glycemic Status” | >

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Patients treated with fixed-duration ibrutinib (Imbruvica) plus venetoclax (Venclexta) achieved higher undetectable minimal residual disease (uMRD), progression-free survival (PFS), and overall survival (OS) rates compared with chlorambucil plus obinutuzumab (Gazyva) across most genomic subgroups of chronic lymphocytic leukemia (CLL).1.

Findings come from the phase 3 GLOW study (NCT03462719) in which data were presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). Patients treated with ibrutinib and venetoclax achieved a higher uMRD rate at 3 months (54.7%) after the end of treatment compared with patients treated with obinutuzumab and chlorambucil (39.0%), except patients with trisomy-12, IGLL5 mutation, and mutated immunoglobulin heavy-chain variable (mIGHV).

Read more | >

“Welcome to another exciting episode of AI News! Our top story today is the release of ChatGPT’s DALL-E 3, an AI system that is revolutionizing image generation. We’ll also be discussing Google’s BARD and its recent upgrade, as well as the impressive $40M funding received by Legit Security to protect AI applications from cyber threats. Stay tuned for these stories and more in this episode of AI News. Don’t forget to subscribe and hit the bell icon so you never miss an update on the latest developments in Artificial Intelligence!”

Read more | >